guselkumab
guselkumab: 21 clinical trials tracked.
guselkumab evidence translation
What we can confirm
21 tracked trials
What it means
What to watch
Prepared research question
What is verified about guselkumab, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence4 indications · 4 study sponsors
Clinical Trials (21)showing 10 most recent
CNTO1959ISD4001: A Phase 4, Open-Label, Milk-Only Lactation Study to Assess Concentration of TREMFYA in Breast Milk of Lactating Women Who Are Receiving TREMFYA Therapeutically
Primary endpoint: Guselkumab Concentrations at Steady State in Breast Milk (Q4W Maintenance Regimen)
A Phase 3 Randomized, Double-blind, and Active Controlled, Multi-center Study to Evaluate the Efficacy and Safety of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis
Primary endpoint: Percentage of Participants in Clinical Remission at Week 48
A Phase 3, Randomized, Double-blind, and Active-controlled Multicenter Study to Evaluate the Efficacy and Safety of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
Primary endpoint: Co-Primary: Percentage of Participants with Clinical Remission at Week 48
A Phase 3b, Multicenter, Randomized, Open-Label, Active-Controlled Study to Compare the Efficacy and Safety of Guselkumab Versus Risankizumab in the Treatment of Participants With Moderately to Severely Active Crohn's Disease
Primary endpoint: Number of Participants with Deep Remission at Week 52
SHIFT-IBD: Switching to High-efficacy Anti-IL-23 Guselkumab in Ustekinumab-exposed Persons With Active IBD
Primary endpoint: Rate of participants achieving deep remission in IBD patients treated with guselkumab after switching from ustekinumab
A Phase-IV, Multicenter, Non-Comparative, Open-Label Study Evaluating the Safety and Efficacy of Guselkumab Administered Subcutaneously in the Treatment of Indian Patients With Psoriatic Arthritis
Primary endpoint: Number of Participants With Adverse Events (AEs)
CNTO1959ISD3001: A Phase 3, Multicenter, Open-label, Basket, Long-term Extension Study to Evaluate the Safety of Guselkumab in Pediatric Participants With Crohn's Disease, Ulcerative Colitis, or Juvenile Psoriatic Arthritis
Primary endpoint: Number of Participants with Treatment-Emergent Adverse Events as Assessment of Safety
VOICE-Characterization of Early Response to Vedolizumab and IL-23 Antagonists in Participants With Crohn's Disease Using Patient-Reported Outcome Measures: A Prospective Observational Study
Primary endpoint: To assess time of onset of biologic therapy in pain interference
A Phase 3, Multicenter, Randomized, Platform Study of p19 Inhibition of the IL-23 Pathway to Establish Efficacy in Pediatric Crohn's Disease
Primary endpoint: Percentage of Participants with Clinical Remission at Week 52
A Phase 3 Randomized, Open-label Induction, Double-blind Maintenance, Parallel-group, Multicenter Protocol to Evaluate the Efficacy, Safety, and Pharmacokinetics of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis
Primary endpoint: Percentage of Participants with Clinical Remission at Week 56